Literature DB >> 8439979

Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.

L M Weiner1, G R Hudes, J Kitson, J Walczak, P Watts, S Litwin, P J O'Dwyer.   

Abstract

In a phase II clinical trial of 5-fluorouracil (5FU) plus N-(phosphonacetyl)-L-aspartate (PALA) therapy administration, a number of slowly developing clinical responses were observed. Because of this, a variety of immune parameters were sequentially studied in 21 patients on this trial. Of the 21 patients studied, 20 provided sufficient samples to compare baseline with subsequent values, 10 of the 20 patients responded to treatment. Responders and non-responders did not differ in any studied parameter at baseline. After 2 months of therapy, non-specific monocyte cytotoxicity (NSMC), antibody-dependent monocyte cytotoxicity (ADMC) and natural killer (NK) activity were higher in the entire study population, but these increases were not statistically significant. When responders and non-responders were evaluated separately, it was apparent that the trend was due solely to the changes observed in the responding patient population. When mean lysis values for each patient group were determined for each studied time point, it was possible to generate a mean area under the cytotoxicity/time curve (AUC) for each studied parameter. NSMC and ADMC did not differ in responders and non-responders. However, NK activity was significantly greater by mean AUC analysis (P = 0.006) in the responding group; NK activity was maintained in the responders, but decreased in non-responders. When lymphocyte and monocyte expression of the surface markers beta 2-microglobulin, HLA-DR, CD56, HNK-1, CD16 and interleukin-2 receptor were evaluated, there were no differences among responders and non-responders at baseline by mean AUC analysis or when comparing baseline with non-baseline values. It is concluded that although baseline immunological characteristics do not identify patients who are likely to respond to weekly 5FU and PALA, treatment is not associated with deleterious effects on the immune effector function parameters evaluated in this study, there being no effects on expression of a variety of associated cell-surface molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439979     DOI: 10.1007/bf01741090

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

Review 1.  5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.

Authors:  J M Hamilton; M Sznol; M A Friedman
Journal:  Important Adv Oncol       Date:  1990

2.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 11 indium-oxine.

Authors:  R H Wiltrout; D Taramelli; H T Holden
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

4.  Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.

Authors:  H F Sears; D Herlyn; Z Steplewski; H Koprowski
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

5.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

6.  The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.

Authors:  S Ben-Efraim; S Shoval; R Ophir
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  In vivo inhibition of concanavalin A-induced suppressor T cells by 5-fluorouracil.

Authors:  T Kataoka; M Nakamura; T Iwaguchi
Journal:  Jpn J Cancer Res       Date:  1985-10

8.  Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.

Authors:  L M Weiner; K Padavic-Shaller; J Kitson; P Watts; R L Krigel; S Litwin
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

9.  Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil.

Authors:  Y Ohta; K Sueki; K Kitta; K Takemoto; H Ishitsuka; Y Yagi
Journal:  Gan       Date:  1980-04

10.  Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon.

Authors:  M Goto; A Mitsuoka; M Sugiyama; M Kitano
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.